Narcolepsy clinical trials are among the most operationally demanding studies in sleep medicine. NT1 prevalence is ~25-50 per 100,000, patients are geographically dispersed, and the primary efficacy endpoints — the Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT) — require standardized, in-lab execution across every visit.
The orexin era
Orexin (hypocretin) 2 receptor agonists have re-energized narcolepsy pipelines. Programs from Takeda, Alkermes, Centessa, and others are advancing NT1 candidates through Phase 2 and 3. For sponsors, this means competition for a small NT1 patient pool and pressure to differentiate on both efficacy (MWT sleep latency) and quality-of-life measures.
MSLT and MWT execution
- Standardized nap protocols across sites — controlled meals, caffeine washout, actigraphy-verified sleep in the prior 7 days.
- Centralized scoring for sleep-onset REM periods and mean sleep latency.
- PSG the night before MSLT — minimum 6 hours total sleep time to interpret the day's naps.
- Actigraphy adherence — non-adherent runs invalidate the MSLT.
Recruiting a rare-disease population
Sleep patient recruitment for NT1 depends on a curated network of academic sleep centers plus patient advocacy channels (Project Sleep, Narcolepsy Network). Our sleep research CRO maintains standing relationships with high-enrolling narcolepsy sites and can pre-identify HLA DQB1*06:02-positive candidates through partner labs.
Beyond MSLT — capturing real-world burden
Regulators and payers want more than sleep latency numbers. Successful programs pair MSLT/MWT with the Narcolepsy Severity Scale, weekly cataplexy diaries, and ecological momentary assessment via smartphone. Sponsors building app-based endpoints should review our digital health CRO approach to validating those measures.